Journal of Medicinal Chemistry · 2020 · 25 citations · 27 references
PharmacyMedicinal ChemistryPharmacologyBioavailabilityDrug DiscoveryMolecular PharmacologyAnemiaEnzyme InhibitionErythropoiesis-stimulating TherapyErythropoietin RegulationFluorescence Polarization ImagingFluorescence Polarization MicroscopyMetabolic Enzyme Inhibition
The design and discovery of a new series of (5-alkynyl-3-hydroxypicolinoyl)glycine inhibitors of prolyl hydroxylase (PHD) are described. These compounds showed potent in vitro inhibitory activity toward PHD2 in a fluorescence polarization-based assay. Remarkably, oral administration of 17, with an IC50 of 64.2 nM toward PHD2, was found to stabilize HIF-α, elevate erythropoietin (EPO), and alleviate anemia in a cisplatin-induced anemia mouse model with an oral dose of 25 mg/kg. Rat and dog studies showed that 17 has good pharmacokinetic properties, with oral bioavailabilities of 55.7 and 54.0%, respectively, and shows excellent safety profiles even at a high dose of 200 mg/kg in these animals. Based on these results, 17 is currently being evaluated in a phase I clinical trial for anemia.
27
A Conserved Family of Prolyl-4-Hydroxylases That Modify HIF
Richard K. Bruick, Steven L. McKnight · Science · 2001 · 2.5K citations
Structural basis for the recognition of hydroxyproline in HIF-1α by pVHL
Wai‐Ching Hon, Michael Wilson, Karl Harlos et al. · Nature · 2002 · 746 citations
Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis
Nan Chen, Chuan‐Ming Hao, Bi‐Cheng Liu et al. · New England Journal of Medicine · 2019 · 613 citations
Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis
Nan Chen, Chuan‐Ming Hao, Xiaomei Peng et al. · New England Journal of Medicine · 2019 · 568 citations · Full text